Medindia

X

Questcor Announces Second Quarter 2010 Earnings Release Date and Conference Call

Thursday, July 15, 2010 Press Release J E 4
Advertisement


UNION CITY, Calif., July 15 Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that it will release financial results for the second quarter ended June 30, 2010 on Wednesday, July 28, 2010 after the market close. The Company will host a conference call and webcast on Wednesday, July 28, 2010 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss the Company's second quarter results and current corporate developments. The dial-in number for the conference call is 866-225-8754 for domestic participants and 480-629-9692 for international participants.

A taped replay of the conference call will also be available beginning approximately one hour after the call's conclusion and will be available for seven days. This replay can be accessed by dialing 800-406-7325 for domestic callers and 303-590-3030 for international callers, both using passcode 4330467#. To access the live webcast of the call, go to Questcor Pharmaceuticals' website at www.questcor.com. An archived webcast will also be available at www.questcor.com.

About Questcor

Questcor Pharmaceuticals, Inc. is a pharmaceutical company that markets H.P. ActharŽ Gel (repository corticotropin injection). H.P. Acthar Gel ("Acthar") is an injectable drug that is approved for the treatment of certain disorders with an inflammatory component, including the treatment of exacerbations associated with multiple sclerosis ("MS") and to induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that is due to lupus erythamatosus. In addition, Acthar is not indicated for, but is used in treating patients with infantile spasms ("IS"), a rare form of refractory childhood epilepsy, and opsoclonus myoclonus syndrome, a rare autoimmune-related childhood neurological disorder. The Company also markets DoralŽ (quazepam), which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. For more information, please visit www.questcor.com.

SOURCE Questcor Pharmaceuticals, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Second Quarter 2010 Results Date Notification - Au...
S
NBTY Agrees to Be Acquired by the Carlyle Group fo...